This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What Makes Cybin Inc. (CYBN) a New Buy Stock
by Zacks Equity Research
Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
by Zacks Equity Research
Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
by Kanishka Das
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Brian's Big Idea on Biotech
by Brian Bolan
A look at drugs for drug addiction and the biotech space.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Bull Of The Day: Cybin (CYBN)
by Brian Bolan
Instead of a hangover, the side effect from this treatment has been described as an "after glow."
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
by Zacks Equity Research
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.